April 22, 2024
The U.S. Supreme Court on Monday rejected Vanda Pharmaceuticals Inc.'s request for review of how the Federal Circuit is deciding whether patents are invalid as obvious, ending the company's attempt to revive patents covering its sleep disorder drug Hetlioz.
March 22, 2024
Teva Pharmaceuticals and Apotex have said the U.S. Supreme Court should reject a petition from Vanda Pharmaceuticals, which said the Federal Circuit "charted its own course" when it invalidated its sleep drug patents as obvious.
February 20, 2024
The National Association of Patent Practitioners, the American Council of the Blind and other groups have thrown their support behind Vanda's U.S. Supreme Court appeal of decisions invalidating its patents on Hetlioz, a drug for the blind.
February 08, 2024
Two pharmaceutical companies have urged the U.S. Supreme Court to take up an argument over obviousness in drug patent invalidations, telling the high court the Federal Circuit erred when it found there was a reasonable expectation of success just because a clinical trial was done.
January 25, 2024
The U.S. Supreme Court receives thousands of petitions for review each term, but only a few make the news. Here, Law360 looks at four petitions filed in the past two weeks that you might've missed, including questions over pleading standards, the correct obviousness test to apply in patent disputes, whether Americans with Disabilities Act retaliation plaintiffs are entitled to jury trials, and how the government should prosecute spoofing.
January 12, 2024
Vanda Pharmaceuticals has asked the U.S. Supreme Court to weigh in on a Federal Circuit decision affirming an obviousness finding of several patents Vanda had asserted against rivals Teva Pharmaceuticals and Apotex, saying the appellate court's decision is at odds with high court precedent.